A thorny pathway of macrophage activating factor (GcMAF): from bench to bedside

Vitamin D3 Binding Protein (DBP) is a multifunctional glycoprotein whose main role is to transport vitamin D3 and its metabolites, but it also is the precursor of the macrophage activating factor (GcMAF). DBP is converted to GcMAF as a result of site-specific selective deglycosylation under the action of β-galactosidase and sialidase, localized on activated B and T cells, respectively. GcMAF exerts its biological activity primarily as the capability of activating macrophages by enhancing their phagocytic function and producing ROS. Activation results in elevated expression of the specific macrophageal surface receptors involved in the recognition of tumor-associated antigens, as well as in the implementation of direct anticancer activity by inducing the apoptosis or necrosis of tumor cells. Increased interest in GcMAF is associated with its potential to be used in the clinic as a new antitumor drug. Besides its anti-tumor activity, GcMAF exerts a potential against a number of viral and neurodegenerative diseases associated with increased activity of N-acetylgalactosaminidase (nagalase) in the blood serum of patients. Nagalase is an enzyme that completely (rather than selectively) deglycosylates DBP so it cannot be converted to GcMAF, leading to immunodeficiency. Circulating DBP is composed of unmodified and O-glycosylated molecules with the glycosylation degree being dependent on the allelic variants of the gene encoding DBP. The role of DBP in the resistance of organism against a number of diseases is supported by the increased risk of a variety of severe illnesses (amyotrophic lateral sclerosis, colorectal cancer etc.) in patients deficient for GcMAF due to homozygosity for defective DBP alleles. In this review, we also will examine in detail the current data i) on the structure and functions of DBP, as the main precursor of GcMAF, ii) on the main mechanisms of GcMAF anticancer effect, iii) on the tumor strategy for neutralizing GcMAF activity, iv) on the results of GcMAF clinical trials in various cancers; and will discuss the available controversies regarding the positioning of GcMAF as an effective antitumor drug. 

1. Sakhno L.V., Shevela E.Ya., Tikhonova M.A., Ostanin A.A., Chernykh E.R. Molecular mechanisms of M2 macrophage immunosuppressive activity. Immunologia = Immunology. 2016;37(6):311-315. DOI 10.18821/0206-49522016-37-6-311-315. (in Russian)

2. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008;222(1):155-161. DOI 10.1111/j.1600-065X.2008.00607.x.

3. Bradstreet J.J., Vogelaar E., Thyer L. Initial observations of elevated alpha-N-acetylgalactosaminidase activity associated with autism and observed reductions from Gcprotein-macrophage activating factor injections. Autism Insights. 2012;4:31-38. DOI 10.4137/AUI.S10485.

4. Delanghe J.R., Speeckaert R., Speeckaert M.M. Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(5):773-786. DOI 10.1016/j.beem.2015.06.006.

5. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002;3(11):991-998. DOI 10.1038/ni1102-991.

6. Gregory K.J., Zhao B., Bielenberg D.R., Dridi S., Wu J., Jiang W., Huang B., Pirie-Shepherd S., Fannon M. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 2010;5(10):e13428. DOI 10.1371/journal.pone.0013428.

7. Haddad J.G., Hu Y.Z., Kowalski M.A., Laramore C., Ray K., Robzyk P., Cooke N.E. Identification of the steroland actin-binding domains of plasma vitamin D binding protein (Gc-globulin). Biochemistry. 1992;31(31):7174-7181. DOI 10.1021/bi00146a021.

8. Homma S., Yamamoto M., Yamamoto N. Vitamin D-binding protein (group-specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol. Cell Biol. 1993;71(Pt. 4):249-257. DOI 10.1038/icb.1993.29.

9. Inui T., Kuchiike D., Kubo K., Mette M., Uto Y., Hori H., Sakamoto N. Clinical experience of integrative cancer immunotherapy with GcMAF. Anticancer Res. 2013;33(7):2917-2919.

10. Ioannou Y.A., Bishop D.F., Desnick R.J. Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J. Cell Biol. 1992;119: 1137-1150. DOI 10.1083/jcb.119.5.1137.

11. Ishikawa M., Inoue T., Inui T., Kuchiike D., Kubo K., Uto Y., Nishikata T. A novel assay system for macrophage-activating factor activity using a human U937 cell line. Anticancer Res. 2014;34(8):45774581.

12. Kanan R.M., Cook D.B., Datta H.K. Lectin immunoassay for macrophage-activating factor (Gc-MAF) produced by deglycosylation of Gc-globulevidence for noninducible generation of Gc-MAF. Clin. Chem. 2000;46:412-414.

13. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1-14. DOI 10.1111/j.1365-2567.2007.02587.x.

14. Kisker O., Onizuka S., Becker C.M., Fannon M., Flynn E., D’Amato R., Zetter B., Folkman J., Ray R., Swamy N., Pirie-Shepherd S. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia. 2003; 5(1):32-40. DOI 10.1016/S1476-5586(03)80015-5.

15. Korbelik M., Naraparaju V.R., Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br. J. Cancer. 1997;75(2):202-207. DOI 10.1038/bjc.1997.34.

16. Kuchiike D., Uto Y., Mukai H., Ishiyama N., Abe C., Tanaka D., Kawai T., Kubo K., Mette M., Inui T., Endo Y., Hori H. Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity. Anticancer Res. 2013;33(7):2881-2885.

17. Malik S., Fu L., Juras D.J., Karmali M., Wong B.Y., Gozdzik A., Cole D.E. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit. Rev. Clin. Lab. Sci. 2013;50(1): 1-22. DOI 10.3109/10408363.2012.750262.

18. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11): 549-555. DOI 10.1016/S1471-4906(02)02302-5.

19. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006;177(10):7303-7311. DOI 10.4049/jimmunol.177.10.7303.

20. Matsuura T., Uematsu T., Yamaoka M., Furusawa K. Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor. Int. J. Oncol. 2004;24(3):521-528. DOI 10.3892/ijo.24.3.521.

21. McCarty F. Overview of macrophage activating factor and the nagalase assay – potential for control of micrometastatic or early primary cancer. 2013. Available at https://pdfs.semanticscholar.org/8c6d/d28ae1280f52d857145bbd7b14d4a6146e2d.pdf.

22. Mohamad S.B., Nagasawa H., Uto Y., Hori H. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 2002a;132(1):1-8. DOI 10.1016/S1095-6433(02)00190-3.

23. Mohamad S.B., Nagasawa H., Uto Y., Hori H. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities. Anticancer Res. 2002b; 22(6C):4297-4300.

24. Morales E.M. GcMAF: a polemic or a highly promising molecule? World Scientific News. 2017;65:20-36.

25. Nagasawa H., Uto Y., Sasaki H., Okamura N., Murakami A., Kubo S., Kirk K.L., Hori H. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res. 2005;25: 3689-3696.

26. Nonaka K., Onizuka S., Ishibashi H., Uto Y., Hori H., Nakayama T., Matsuura N., Kanematsu T., Fujioka H. Vitamin D binding proteinmacrophage activating factor inhibits HCC in SCID mice. J. Surg. Res. 2012;172(1):116-122. DOI 10.1016/j.jss.2010.07.057.

27. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 2001;23(2-3):263-272. DOI 10.1385/IR:23:2-3:263.

28. Otterbein L.R., Cosio C., Graceffa P., Dominguez R. Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actin-scavenger system. Proc. Natl. Acad. Sci. USA. 2002;99:8003-8008. DOI 10.1073/pnas.122126299.

29. Pacini S., Morucci G., Punzi T., Gulisano M., Ruggiero M. Gc proteinderived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol. Immunother. 2011;60(4):479-485. DOI 10.1007/s00262-010-0953-7.

30. Pacini S., Morucci G., Punzi T., Gulisano M., Ruggiero M., Amato M., Aterini S. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. J. Nephrol. 2012a;25(4):577-581. DOI 10.5301/jn.5000035.

31. Pacini S., Punzi T., Morucci G., Gulisano M., Ruggiero M. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res. 2012b;32(1):45-52.

32. Rehder D.S., Nelson R.W., Borges C.R. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009;18(10): 2036-2042. DOI 10.1002/pro.214.

33. Saburi E., Saburi A., Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Caspian J. Intern. Med. 2017;8(4):228-238. DOI 10.22088/cjim.8.4.228.

34. Song Y.H., Naumova A.K., Liebhaber S.A., Cooke N.E. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res. 1999;9(6):581-587.

35. Thyer L., Ward E., Smith R., Branca J.J., Morucci G., Gulisano M., Noakes D., Eslinger R., Pacini S. GC protein-derived macrophageactivating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology. 2013a;2(8):e25769. DOI 10.4161/onci.25769.

36. Thyer L., Ward E., Smith R., Fiore M.G., Magherini S., Branca J.J., Morucci G., Gulisano M., Ruggiero M., Pacini S. A novel role for a major component of the vitamin D axis: vitamin D binding proteinderived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients. 2013b;5(7):2577-2589. DOI 10.3390/nu5072577.

37. Toutirais O., Chartier P., Dubois D., Bouet F., Leveque J., CatrosQuemener V., Genetet N. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur. Cytokine Netw. 2003;14(4):246-255.

38. Toyohara Y., Hashitani S., Kishimoto H., Noguchi K., Yamamoto N., Urade M. Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line. Oncol. Lett. 2011;2(4):685-691. DOI 10.3892/ol.2011.306.

39. Ugarte A., Bouche G., Meheus L. Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al. Cancer Immunol. Immunother. 2014;63(12):1347-1348. DOI 10.1007/s00262-014-1587-y.

40. Uto Y., Hori H., Kubo K., Ichihashi M., Sakamoto N., Mette M., Inui T. GcMAF: our next-generation immunotherapy. Nature. 2012;485: S67-S70.

41. Verboven C., Rabijns A., De Maeyer M., Van Baelen H., Bouillon R., De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat. Struct. Biol. 2002;9(2):131136. DOI 10.1038/nsb754.

42. Yamamoto N., Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc. Natl. Acad. Sci. USA. 1991;88(19):8539-8543. DOI 10.1073/pnas. 88.19.8539.

43. Yamamoto N., Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J. Immunol. 1993;151(5):2794-2802.

44. Yamamoto N., Naraparaju V.R., Asbell S.O. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 1996;56(12):2827-2831.

45. Yamamoto N., Suyama H., Nakazato H., Yamamoto N., Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol. Immunother. 2008a;57:1007-1016. DOI 10.1007/s00262-007-0431-z.

46. Yamamoto N., Suyama H., Yamamoto N. Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl. Oncol. 2008b;1(2):65-72. DOI 10.1593/tlo.08106.

47. Yamamoto N., Suyama H., Yamamoto N., Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding proteinderived macrophage activating factor (GcMAF). Int. J. Cancer. 2008c;122:461-467. DOI 10.1002/ijc.23107.

48. Yamamoto N., Ushijima N., Koga Y. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J. Med. Virol. 2009;81:16-26. DOI 10.1002/jmv.21376.